摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(3-oxo-4-phenylbutyryl)piperidine-1-carboxylate | 301219-11-4

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(3-oxo-4-phenylbutyryl)piperidine-1-carboxylate
英文别名
1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-4-phenyl-butane-1,3-dione;4-(3-oxo-4-phenyl-butyryl)-piperidine-1-carboxylic acid tert-butyl ester;1-(1-(t-Butoxycarbonyl)piperidin-4-yl)-4-phenylbutane-1,3-dione;Tert-butyl 4-(3-oxo-4-phenylbutanoyl)piperidine-1-carboxylate
tert-butyl 4-(3-oxo-4-phenylbutyryl)piperidine-1-carboxylate化学式
CAS
301219-11-4
化学式
C20H27NO4
mdl
——
分子量
345.439
InChiKey
IOOKMCPXIRFOEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    25
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    63.7
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933399090

SDS

SDS:c3163f3eb24e3916d231df404b267b84
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 4-(3-oxo-4-phenylbutyryl)piperidine-1-carboxylate盐酸羟胺三乙酰氧基硼氢化钠N,N-二异丙基乙胺 作用下, 以 乙醇1,2-二氯乙烷 为溶剂, 生成 (R)-{(3S,4S)-3-[4-(5-Benzyl-isoxazol-3-yl)-piperidin-1-ylmethyl]-4-phenyl-pyrrolidin-1-yl}-cyclohexyl-acetic acid benzyl ester
    参考文献:
    名称:
    Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains
    摘要:
    Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2003.12.004
  • 作为产物:
    参考文献:
    名称:
    Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains
    摘要:
    Replacement of the flexible connecting chains between the piperidine moiety and an aromatic group in previous CCR5 antagonists with heterocycles, such as pyrazole and isoxazole, provided potent CCR5 antagonists with excellent anti-HIV-1 activity in vitro. SAR studies revealed optimal placement of an unsubstituted nitrogen atom in the heterocycle to be meta to the bond connected to the 4-position of piperidine. Truncation of a benzyl group to a phenyl group afforded compounds with dramatically improved oral bioavailability, albeit with reduced activity. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2003.12.004
点击查看最新优质反应信息

文献信息

  • Modulators of CCR5 chemokine receptor activity
    申请人:——
    公开号:US20020193407A1
    公开(公告)日:2002-12-19
    Compounds of Formula I: 1 (wherein R 1 , R 2 , R 3 , R 4 , Q, and X are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    化合物的化学式I: 1 (其中R 1 ,R 2 ,R 3 ,R 4 ,Q和X在此处定义)已被描述。这些化合物是CCR5趋化因子受体活性的调节剂。这些化合物在预防或治疗HIV感染以及治疗艾滋病方面是有用的,可以作为化合物或药学上可接受的盐,或作为药物组成部分,可选地与其他抗病毒药物,免疫调节剂,抗生素或疫苗组合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
  • N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
    申请人:——
    公开号:US20040002504A1
    公开(公告)日:2004-01-01
    The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: 1 wherein, generally, Q is 2 R 1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C 1-4 alkyl or halogen, such as methyl, fluorine or bromine; R 2 is hydrogen or C 1-4 alkyl such as methyl; R 3 is phenyl; R 4 is hydrogen; R 5 is hydrogen or C 1-6 alkylcarbonyl such as methylcarbonyl; X is —SO 2 — or —C(O)N(R 2 )SO 2 — where R 2 is preferably hydrogen; Y is a bond, CH 2 or Z 1 where Z 1 is —N(R f )— in which R f is C 1-6 alkylcarbonyl such as ethylcarbonyl; and R 6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C 1-6 alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.
    本发明提供了一种治疗患有疾病(如精神分裂症)的受试者的方法,其中该疾病的治疗需要使用NK-3拮抗剂,包括向该受试者施用化合物I的治疗有效量: 1 其中,通常情况下, Q是 2 R 1 是苄基、苯基、噻吩或咪唑基,可选择地用C 1-4 烷基或卤素(如甲基、氟或溴)取代; R 2 是氢或C 1-4 烷基,如甲基; R 3 是苯基; R 4 是氢; R 5 是氢或C 1-6 烷基羰基,如甲基羰基; X是—SO 2 —或—C(O)N(R 2 )SO 2 —,其中R 2 最好是氢; Y是键、CH 2 或Z 1 ,其中Z 1 是—N(R f )—,其中R f 是C 1-6 烷基羰基,如乙基羰基;以及 R 6 是苯基、吡唑基、吡啶基、嘧啶基或苯并咪唑基,可选择地用来自C 1-6 烷基和苄基的一个或两个基团取代,如甲基、乙基和苄基; 或其药学上可接受的盐。
  • Pyrrolidine modulators of CCR5 chemokine receptor activity
    申请人:——
    公开号:US20020094989A1
    公开(公告)日:2002-07-18
    Pyrrolidine compounds of Formula I: 1 (wherein 1 , R 2 , R 3 , R 4 , R 5 ,R 6a , R 6b , R 7 and R 8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Pyrrolidine化合物的化学式I: 1 (其中 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6a ,R 6b ,R 7 和R 8 在此定义)已被描述。这些化合物是CCR5趋化因子受体活性的调节剂。这些化合物可用于预防或治疗HIV感染和治疗艾滋病,作为化合物或药学上可接受的盐,或作为药物组成部分,可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
  • Pyrrolidine modulators of chemokine receptor activity
    申请人:Merck & Co., Inc.
    公开号:US06248755B1
    公开(公告)日:2001-06-19
    The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    本发明涉及式I的吡咯烷化合物: (其中R1,R2,R3,R4,R5,R6,R14和n的定义如本文中)这些化合物可用作调节化学趋化因子受体活性的调节剂。特别是,这些化合物可用作调节CCR-5和/或CCR-3的化学趋化因子受体的调节剂。
  • [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
    申请人:ASTRAZENECA AB
    公开号:WO2004099178A1
    公开(公告)日:2004-11-18
    Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
    公式(I)的化合物:包含它们的组合物,制备它们的方法以及它们在医学疗法中的用途(例如在温血动物中调节CCR5受体活性)。
查看更多